Natera (NTRA) Q3 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2026 earnings summary
6 Nov, 2026Executive summary
Q3 revenue was $794.0M, up 34.1% YoY; total tests processed reached 1.093M, up 22.3%, and clinical MRD oncology units were ~316K, up >56%.
FY2026 revenue guidance rose to $3.005B-$3.035B, a $140M midpoint increase; the 2029 revenue target is $6B.
Net loss narrowed to $59.9M, or $0.42 per diluted share, from $87.5M, or $0.64, in Q3 2025.
Growth reflected higher test volumes and ASP improvements, while R&D, lab expansion and commercialization spending weighed on profitability.
Financial highlights
Q3 revenue was $794.0M versus $592.2M a year earlier; revenue excluding true-ups grew ~42% YoY.
Q3 gross profit was $513.5M and GAAP gross margin was 64.7%, versus 64.9% YoY; margin excluding true-ups was 63.2%.
Q3 operating expenses were $862.3M, up 25.0% YoY; R&D was $242.4M and SG&A was $333.7M.
Nine-month revenue was $2.243B versus $1.641B; net loss narrowed to $212.0M from $255.4M.
Outlook and guidance
FY2026 revenue guidance increased to $3.005B-$3.035B from $2.850B-$2.910B; assumptions include continued volume growth and exclude true-ups.
FY2026 gross-margin guidance is 64%-66%; SG&A guidance is $1.225B-$1.300B and R&D guidance is $825M-$925M.
2027 preliminary outlook assumes unit growth comparable to 2026, relatively steady ASPs, gross margin within the FY2026 guide range and OPEX growth of 10%-12%.
The 2029 revenue target is $6B, supported by oncology growth, global expansion, pharma and data licensing, and continued growth in other areas.
Latest events from Natera
- A $6B 2029 target builds on Signatera growth, with screening and Japan extending the runway.NTRA
UBS Global Healthcare Conference - A $6B 2029 target and expanding cancer-testing opportunity frame the outlook.NTRA
8th Annual Wolfe Research Healthcare Conference - Record growth, expanding global reach, and innovation drive strong financial and operational results.NTRA
2026 Global Healthcare Conference - Record MRD growth, expanding biopharma ties, and innovation set the stage for sustained expansion.NTRA
Morgan Stanley 24th Annual Global Healthcare Conference - Record Q2 growth, product innovation, and global expansion drive strong outlook.NTRA
Canaccord Genuity's 46th Annual Growth Conference - Revenue up 38% to $753M, record test volumes, improved margins, and raised guidance.NTRA
Q2 2026 - Record growth, innovation, and AI-driven strategies are accelerating adoption and market expansion.NTRA
Morgan Stanley 23rd Annual Global Healthcare Conference - Q1 2025 revenue up 37% to $502M, record oncology growth, margin at 63.1%, net loss steady.NTRA
Q1 2025 - Record growth, innovation, and clinical momentum set the stage for major milestones in 2025.NTRA
43rd Annual J.P. Morgan Healthcare Conference 2025